Startups
HepaRegeniX
https://heparegenix.comSmall molecule MKK4 inhibitors to treat acute and chronic liver diseases
Summary
Total Funding
$37.6M
- Series C (2024-07-10) $16.0M
- Series B (2020-01-24) $12.1M
- Series A (2017-01-06) $9.5M
Investors
Novo A/S Series C
Novo A/S Series C
High-Tech Gründerfonds Series C
Boehringer Ingelheim Venture Fund Series C
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable